Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. [Phase 3]

View source ↗

Summary

This update notes a Phase 3 trial evaluating SCTB14 as first-line therapy for non-small cell lung cancer, which is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SCTB14

Snippet

Sponsor: Sinocelltech Ltd. | Conditions: Non-Small Cell Lung Carcinoma (NSCLC) | Phase 3 | Status: RECRUITING